We employ this model to structure the discussion of the selective use of CAC measurements in ASCVD risk assessment for allocation of aspirin, BP management, cholesterol medications such as statins, and diabetes medications—in particular GLP‐1 receptor agonizts—in primary prevention. The gene discussed is GLP1R; the disease is diabetes mellitus.